Compare Aurora Cannabis Inc (ACB) vs Home Depot Inc (HD) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Home Depot (HD) trades at $354.48, down 0.32% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $368.75. The stock shows strong profitability with a net margin of 8.41% and ROE of 128.38%, though recent earnings have been mixed with a Q3 2025 miss but Q4 2025 and Q1 2026 beats. Revenue grew to $159.51 billion in 2025, while cash flow from operations remains robust at $19.81 billion, supporting a recent dividend of $2.33 per share.

The outlook is supported by analyst optimism (59% buy ratings) and Pro business growth, but risks include weakening big-ticket demand, margin pressures from investments, and sensitivity to housing market trends. The stock's valuation at a P/E of 24.91 may limit near-term upside if earnings growth slows.